Imeglimin

Imeglimin (EMD 387008) is an oral glucose-lowering agent. Imeglimin improves insulin sensitivity. Imeglimin also reduces reactive oxygen species (ROS) production, increases mitochondrial DNA and improves mitochondrial function[1].

Product Specifications

CAS Number

[775351-65-0]

Product Name Alternative

EMD 387008

UNSPSC

12352005

Hazard Statement

H302

Target

Mitochondrial Metabolism; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/imeglimin.html

Concentration

10mM

Purity

99.10

Solubility

DMSO : 32 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

NC1=N[C@@H](C)N=C(N(C)C)N1

Molecular Formula

C6H13N5

Molecular Weight

155.20

Precautions

P264-P270-P330-P501

References & Citations

[1]Vial G, et al. Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrialfunction in liver of a high-fat, high-sucrose diet mice model. Diabetes. 2015 Jun;64 (6) :2254-64.|[2]Detaille D, et al. Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell Death Discov. 2016 Jan 18;2:15072.